Main variables;No. of employees;Total
No. of companies carrying out R&D in Biotechnology;Fewer than 250 employees;1.006
No. of companies carrying out R&D in Biotechnology;250 or more employees;73
No. of companies carrying out R&D in Biotechnology;Total;1.079
%Companies according to biotechnology used: Genetic code;Fewer than 250 employees;34
%Companies according to biotechnology used: Genetic code;250 or more employees;55
%Companies according to biotechnology used: Genetic code;Total;35
%Companies according to biotechnology used: Functional units;Fewer than 250 employees;44
%Companies according to biotechnology used: Functional units;250 or more employees;53
%Companies according to biotechnology used: Functional units;Total;44
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Fewer than 250 employees;25
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;250 or more employees;47
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Total;26
%Companies according to biotechnology used: Bioprocesses;Fewer than 250 employees;48
%Companies according to biotechnology used: Bioprocesses;250 or more employees;64
%Companies according to biotechnology used: Bioprocesses;Total;49
%Companies according to biotechnology used: Sub-cellular organisms;Fewer than 250 employees;8
%Companies according to biotechnology used: Sub-cellular organisms;250 or more employees;15
%Companies according to biotechnology used: Sub-cellular organisms;Total;8
%Companies according to biotechnology used: Bio-computing;Fewer than 250 employees;23
%Companies according to biotechnology used: Bio-computing;250 or more employees;23
%Companies according to biotechnology used: Bio-computing;Total;23
%Companies according to biotechnology used: Nanobiotechnology;Fewer than 250 employees;15
%Companies according to biotechnology used: Nanobiotechnology;250 or more employees;12
%Companies according to biotechnology used: Nanobiotechnology;Total;15
%Companies according to biotechnology used: Other;Fewer than 250 employees;12
%Companies according to biotechnology used: Other;250 or more employees;11
%Companies according to biotechnology used: Other;Total;12
Companies in which biotechnology activities are: Main and/or exclusive;Fewer than 250 employees;503
Companies in which biotechnology activities are: Main and/or exclusive;250 or more employees;16
Companies in which biotechnology activities are: Main and/or exclusive;Total;519
Companies in which biotechnology activities are: A secondary line of business;Fewer than 250 employees;158
Companies in which biotechnology activities are: A secondary line of business;250 or more employees;21
Companies in which biotechnology activities are: A secondary line of business;Total;179
Companies in which biotechnology activities are: A tool necessary for production;Fewer than 250 employees;345
Companies in which biotechnology activities are: A tool necessary for production;250 or more employees;36
Companies in which biotechnology activities are: A tool necessary for production;Total;381
%Company by field(s) of ultimate application of biotechnology use: Human Health;Fewer than 250 employees;47
%Company by field(s) of ultimate application of biotechnology use: Human Health;250 or more employees;51
%Company by field(s) of ultimate application of biotechnology use: Human Health;Total;48
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Fewer than 250 employees;22
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;250 or more employees;4
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Total;21
%Company by field(s) of ultimate application of biotechnology use: Food products;Fewer than 250 employees;33
%Company by field(s) of ultimate application of biotechnology use: Food products;250 or more employees;34
%Company by field(s) of ultimate application of biotechnology use: Food products;Total;33
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Fewer than 250 employees;22
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;250 or more employees;21
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Total;22
%Company by field(s) of ultimate application of biotechnology use: Environment;Fewer than 250 employees;17
%Company by field(s) of ultimate application of biotechnology use: Environment;250 or more employees;21
%Company by field(s) of ultimate application of biotechnology use: Environment;Total;17
%Company by field(s) of ultimate application of biotechnology use: Industry;Fewer than 250 employees;15
%Company by field(s) of ultimate application of biotechnology use: Industry;250 or more employees;8
%Company by field(s) of ultimate application of biotechnology use: Industry;Total;15
Personnel in R&D in biotechnology (no. of persons);Fewer than 250 employees;7.556
Personnel in R&D in biotechnology (no. of persons);250 or more employees;2.239
Personnel in R&D in biotechnology (no. of persons);Total;9.795
Personnel in R&D in biotechnology (no. of persons): Researchers;Fewer than 250 employees;4.379
Personnel in R&D in biotechnology (no. of persons): Researchers;250 or more employees;1.194
Personnel in R&D in biotechnology (no. of persons): Researchers;Total;5.573
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;Fewer than 250 employees;3.177
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;250 or more employees;1.045
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;Total;4.222
Personnel in R&D in biotechnology (no. of persons): women;Fewer than 250 employees;4.032
Personnel in R&D in biotechnology (no. of persons): women;250 or more employees;1.267
Personnel in R&D in biotechnology (no. of persons): women;Total;5.298
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;Fewer than 250 employees;2.279
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;250 or more employees;646
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;Total;2.925
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;Fewer than 250 employees;1.752
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;250 or more employees;621
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;Total;2.373
Personnel in R&D in biotechnology (FTE);Fewer than 250 employees;5.209,9
Personnel in R&D in biotechnology (FTE);250 or more employees;1.618,7
Personnel in R&D in biotechnology (FTE);Total;6.828,6
Personnel in R&D in biotechnology (FTE): Researchers;Fewer than 250 employees;3.191,6
Personnel in R&D in biotechnology (FTE): Researchers;250 or more employees;914,9
Personnel in R&D in biotechnology (FTE): Researchers;Total;4.106,5
Personnel in R&D in biotechnology (FTE): Technicians and assistants;Fewer than 250 employees;2.018,3
Personnel in R&D in biotechnology (FTE): Technicians and assistants;250 or more employees;703,8
Personnel in R&D in biotechnology (FTE): Technicians and assistants;Total;2.722,1
Personnel in R&D in biotechnology (FTE): women;Fewer than 250 employees;2.872,2
Personnel in R&D in biotechnology (FTE): women;250 or more employees;939,6
Personnel in R&D in biotechnology (FTE): women;Total;3.811,7
Personnel in R&D in biotechnology (FTE): (women) Researchers;Fewer than 250 employees;1.682,6
Personnel in R&D in biotechnology (FTE): (women) Researchers;250 or more employees;508,1
Personnel in R&D in biotechnology (FTE): (women) Researchers;Total;2.190,7
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;Fewer than 250 employees;1.189,5
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;250 or more employees;431,5
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;Total;1.621
Internal expenditure on R&D (thousands of euros);Fewer than 250 employees;402.391
Internal expenditure on R&D (thousands of euros);250 or more employees;131.434
Internal expenditure on R&D (thousands of euros);Total;533.826
1) By nature of the expense: Current expenses;Fewer than 250 employees;365.997
1) By nature of the expense: Current expenses;250 or more employees;126.959
1) By nature of the expense: Current expenses;Total;492.955
1.1) Remuneration to researchers;Fewer than 250 employees;153.274
1.1) Remuneration to researchers;250 or more employees;50.166
1.1) Remuneration to researchers;Total;203.439
1.2) Remuneration to technicians and assistants;Fewer than 250 employees;67.291
1.2) Remuneration to technicians and assistants;250 or more employees;29.559
1.2) Remuneration to technicians and assistants;Total;96.850
1.3) Other current expenses;Fewer than 250 employees;145.432
1.3) Other current expenses;250 or more employees;47.234
1.3) Other current expenses;Total;192.666
2) By nature of the expense: Capital expenses;Fewer than 250 employees;36.395
2) By nature of the expense: Capital expenses;250 or more employees;4.476
2) By nature of the expense: Capital expenses;Total;40.870
2.1) Land and buildings;Fewer than 250 employees;6.634
2.1) Land and buildings;250 or more employees;888
2.1) Land and buildings;Total;7.521
2.2) Equipment and instruments;Fewer than 250 employees;28.690
2.2) Equipment and instruments;250 or more employees;3.388
2.2) Equipment and instruments;Total;32.078
2.3) Acquisition of specific R&D software;Fewer than 250 employees;1.071
2.3) Acquisition of specific R&D software;250 or more employees;200
2.3) Acquisition of specific R&D software;Total;1.270
1) By origin of the funds: National funds;Fewer than 250 employees;329.975
1) By origin of the funds: National funds;250 or more employees;102.895
1) By origin of the funds: National funds;Total;432.869
1.1) Own funds;Fewer than 250 employees;239.006
1.1) Own funds;250 or more employees;80.039
1.1) Own funds;Total;319.046
1.2) From companies;Fewer than 250 employees;30.715
1.2) From companies;250 or more employees;8.538
1.2) From companies;Total;39.253
1.3) Public Administration funds;Fewer than 250 employees;57.667
1.3) Public Administration funds;250 or more employees;12.396
1.3) Public Administration funds;Total;70.063
1.4) From Universities;Fewer than 250 employees;156
1.4) From Universities;250 or more employees;0
1.4) From Universities;Total;156
1.5) From non profit private institutions;Fewer than 250 employees;2.431
1.5) From non profit private institutions;250 or more employees;1.921
1.5) From non profit private institutions;Total;4.351
1) By origin of the funds: Foreign funds;Fewer than 250 employees;72.416
1) By origin of the funds: Foreign funds;250 or more employees;28.540
1) By origin of the funds: Foreign funds;Total;100.956
2.1) From EU programmes;Fewer than 250 employees;18.073
2.1) From EU programmes;250 or more employees;1.998
2.1) From EU programmes;Total;20.070
2.2) Other foreign funds;Fewer than 250 employees;54.344
2.2) Other foreign funds;250 or more employees;26.542
2.2) Other foreign funds;Total;80.886
Purchase of R&D services in biotechnology (thousands of euros);Fewer than 250 employees;76.625
Purchase of R&D services in biotechnology (thousands of euros);250 or more employees;62.000
Purchase of R&D services in biotechnology (thousands of euros);Total;138.625
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Fewer than 250 employees;64.575
Purchase of R&D services in biotechnology (thousands of euros): In Spain;250 or more employees;36.539
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Total;101.114
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Fewer than 250 employees;12.050
Purchase of R&D services in biotechnology (thousands of euros): Abroad;250 or more employees;25.462
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Total;37.512
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Fewer than 250 employees;48
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;250 or more employees;25
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Total;46
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Fewer than 250 employees;13
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;250 or more employees;10
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Total;13
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Fewer than 250 employees;12
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;250 or more employees;12
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Total;12
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Fewer than 250 employees;14
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;250 or more employees;17
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Total;14
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Fewer than 250 employees;19
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;250 or more employees;18
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Total;19
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Fewer than 250 employees;20
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;250 or more employees;12
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Total;19
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Fewer than 250 employees;18
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;250 or more employees;21
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Total;18
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Fewer than 250 employees;37
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;250 or more employees;36
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Total;37
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Fewer than 250 employees;50
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;250 or more employees;44
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Total;49
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Fewer than 250 employees;20
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;250 or more employees;11
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Total;19
% Companies that have requested biotechnology patents in Biotechnology;Fewer than 250 employees;15
% Companies that have requested biotechnology patents in Biotechnology;250 or more employees;22
% Companies that have requested biotechnology patents in Biotechnology;Total;15
Number of patents requested;Fewer than 250 employees;397
Number of patents requested;250 or more employees;69
Number of patents requested;Total;466
% Companies with income of an international origin related to biotechnological activities;Fewer than 250 employees;25,3
% Companies with income of an international origin related to biotechnological activities;250 or more employees;20,5
% Companies with income of an international origin related to biotechnological activities;Total;24,9
% Turnover representing income of an international origin related to biotechnological activities;Fewer than 250 employees;4
% Turnover representing income of an international origin related to biotechnological activities;250 or more employees;0,7
% Turnover representing income of an international origin related to biotechnological activities;Total;0,9
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Fewer than 250 employees;49,5
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;250 or more employees;81
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Total;71,3
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Fewer than 250 employees;50,5
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;250 or more employees;19,1
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Total;28,7
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Fewer than 250 employees;76,2
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;250 or more employees;99,2
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Total;92,2
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Fewer than 250 employees;7,8
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;250 or more employees;.
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Total;2,4
% Income of an international origin related with activities according to the classification: Operating source abroad;Fewer than 250 employees;3,2
% Income of an international origin related with activities according to the classification: Operating source abroad;250 or more employees;0,4
% Income of an international origin related with activities according to the classification: Operating source abroad;Total;1,3
% Income of an international origin related with activities according to the classification: Other;Fewer than 250 employees;12,7
% Income of an international origin related with activities according to the classification: Other;250 or more employees;0,4
% Income of an international origin related with activities according to the classification: Other;Total;4,2